"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04004975","Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib",,"Recruiting","No Results Available","Recurrent Glioblastoma","Drug: Anlotinib","Progress free survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Quality of Life score (QoL)","Shandong Cancer Hospital and Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ShandongCHI006","June 25, 2019","July 25, 2020","July 25, 2021","July 2, 2019",,"July 2, 2019","Shandong cancer hospital, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04004975"
2,"NCT03430791","Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma",,"Recruiting","No Results Available","Recurrent Glioblastoma","Drug: Nivolumab 240 mg IV|Drug: Nivolumab 3 mg/kg|Drug: Ipilimumab 1 mg/kg|Device: NovoTTF200A (Optune)","Objective response rate according to modified iRANO criteria","Baptist Health South Florida|Bristol-Myers Squibb|NovoCure Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-ODI-002","November 5, 2018","August 2020","August 2021","February 13, 2018",,"November 19, 2019","Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03430791"
3,"NCT04051606","Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma",,"Recruiting","No Results Available","Recurrent Glioblastoma","Drug: Regorafenib","Median overall survival (OS)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Objective response rate (ORR)|Progression free survival at 6 months (PFS-6).|Median time to progression (TTP)","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE7318","July 31, 2019","December 2020","December 2021","August 9, 2019",,"February 6, 2020","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04051606"
4,"NCT03856099","TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab",,"Recruiting","No Results Available","Recurrent Glioblastoma","Drug: TTAC-0001","Adverse Events|Progression free survival rate at 4 months|Progression free survival rate at 6 months|Progression free survival|Overall survival|Objective response rate|Disease control rate","PharmAbcine","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC_TTAC-0001_03","November 13, 2019","June 30, 2021","December 30, 2021","February 27, 2019",,"April 14, 2020","Stanford Avanced Medical Center, Stanford, California, United States|Florida Hospital Cancer Institute & Florida Hospital Orlando, Orlando, Florida, United States|Austin Hospital, Heidelberg, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03856099"
5,"NCT03632135","Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma","CSCRGBM","Recruiting","No Results Available","Recurrent Glioblastoma","Diagnostic Test: ChemoID assay|Drug: Chemotherapy","Median Overall Survival (OS)|Overall Survival at 6, 9, and 12 months (OS6mo, OS9mo, OS12mo)|Median Progression Free Survival (PFS)|Progression Free Survival at 4, 6, 9, and 12 months (PFS4mo, PFS6mo, PFS9mo, PFS12mo)|Objective Tumor Response|Quality of life questionnaire","Cordgenics, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","CG01GBM","May 15, 2018","June 30, 2021","January 31, 2022","August 15, 2018",,"November 19, 2019","Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Maine Medical Center Research Institute, Scarborough, Maine, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Garden State Neurology and Neuro-oncology, West Long Branch, New Jersey, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Toledo University, Toledo, Ohio, United States|Providence Cancer Center Oncology, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|The Penn State Univeristy College of Medicine, Hershey, Pennsylvania, United States|Thomas Jefefrson University Hospitals, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Charleston Area Medical Center, Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03632135"
6,"NCT01464177","Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme","GBM Hypo RT","Recruiting","No Results Available","Recurrent Glioblastoma Multiforme","Radiation: Stereotactic hypofractionated RT 5x5Gy|Radiation: Stereotactic hypofractionated RT 5x7Gy","progression free survival|overall survival|local control|toxicity|quality of life","Andre Tsin Chih Chen|University of Sao Paulo","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RT-01/2011","October 2011","October 2020","October 2021","November 3, 2011",,"January 13, 2020","Hospital das Clinicas da Faculdade de Medicina da USP, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT01464177"
7,"NCT03115333","DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma",,"Recruiting","No Results Available","Gliosarcoma|Recurrent Glioblastoma","Diagnostic Test: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging","Change in rCBV within enhancing tumor|OS|CBF|Change in CBF|PFS|rCBV","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Older Adult)","Phase 2","165","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EAF151|NCI-2016-01357|U10CA180820","April 14, 2017","May 7, 2022","May 7, 2027","April 14, 2017",,"February 12, 2020","Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northside Hospital-Forsyth, Cumming, Georgia, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Henry Ford Hospital, Detroit, Michigan, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Community Memorial Hospital, Menomonee Falls, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|The Alyce and Elmore Kraemer Cancer Care Center, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03115333"
8,"NCT04201873","Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",,"Recruiting","No Results Available","Recurrent Glioblastoma","Biological: Dendritic Cell Tumor Cell Lysate Vaccine|Biological: Pembrolizumab|Other: Placebo Administration|Drug: Poly ICLC","Cell cycle-related signature|Expansion of T cell receptor (TCR) clones|Incidence of adverse events (AEs)|6 month progression-free survival (PFS6)|Overall survival (OS)","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp.|Phase One Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","19-001090|NCI-2019-07994|P30CA016042","January 8, 2020","August 1, 2024","August 1, 2025","December 17, 2019",,"February 17, 2020","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04201873"
9,"NCT01849146","Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Recurrent Glioblastoma","Drug: Adavosertib|Radiation: Radiation Therapy|Drug: Temozolomide","Maximum tolerated dose of adavosertib with 6 weeks of radiotherapy and temozolomide (Arm I)|Maximum tolerated dose of adavosertib with adjuvant temozolomide (Arm II)|Incidence of toxicities|Overall survival|Progression-free survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","114","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2013-00858|ABTC 1202|ABTC-1202|UM1CA137443","August 19, 2013","September 28, 2020",,"May 8, 2013",,"May 5, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01849146"
10,"NCT04205357","Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma","SAS-GKRS","Recruiting","No Results Available","Glioma|Glioblastoma|Recurrent Glioblastoma","Drug: Sulfasalazine","Toxicity (Common Terminology Criteria for Adverse Event v 4.0)|Intratumoral Glutathione production|Presence of radiation necrosis|Progression free survival|Overall survival|Quality of life (Functional Assessment of Cancer Therapy-Brain)|Karnofsky performance score (KPS)|Steroid use in mg over time","Haukeland University Hospital|Norwegian Cancer Society|Northwell Health|Weill Medical College of Cornell University|University of Bergen|Helse Stavanger HF","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019/6834","March 1, 2020","December 31, 2022","December 31, 2022","December 19, 2019",,"March 11, 2020","Haukeland University Hospital, Bergen, Norway",,"https://ClinicalTrials.gov/show/NCT04205357"
11,"NCT03360708","Vaccine Therapy in Treating Patients With Recurrent Glioblastoma",,"Recruiting","No Results Available","Giant Cell Glioblastoma|Recurrent Glioblastoma|Recurrent Gliosarcoma","Other: Laboratory Biomarker Analysis|Biological: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine","Incidence of significant toxicity, defined as a dose limiting toxicity (DLT) that is possibly, probably, or definitely related to treatment as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Clinical benefit rate|Duration of response|Feasibility|Overall response rate|Overall survival|Progression-free survival|Time to response","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1772|NCI-2017-02159|P30CA015083","June 3, 2019","December 1, 2022","December 1, 2022","December 4, 2017",,"June 5, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03360708"
12,"NCT03022578","Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma",,"Recruiting","No Results Available","IDH Family Wildtype|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma","Procedure: Laser Interstitial Thermal Therapy|Drug: Lomustine","Disease control rate|Clinical characteristics|Length of hospital stay|Biomarkers in peripheral blood and tumor tissue|Inflammatory/immunologic profile|Overall survival (OS)|Time to progression (TTP)|Incidence of toxicity|Long-term steroid requirements|MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) data","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0443|NCI-2018-01286|P30CA016672","November 7, 2017","November 1, 2021","November 1, 2021","January 16, 2017",,"September 27, 2019","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03022578"
13,"NCT04003649","IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma",,"Recruiting","No Results Available","Recurrent Glioblastoma|Refractory Glioblastoma","Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Biological: Ipilimumab|Biological: Nivolumab|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Incidence of adverse events|Dose-limiting toxicity (DLT)|DLT|Feasibility (neoadjuvant therapy)|Feasibility (adjuvant therapy)|Survival|T cell levels|Cytokine levels in TCF, PB, and CSF|Disease response|Time to progression|Overall survival (OS)|Quality of life|Area under the curve (AUC) for CD3, IFNgamma, and IP-10 levels over time for the DLT evaluation period|CAR T and endogenous cells detected in tumor tissue|IL13Ralpha2 antigen expression levels in tumor tissue|PD‐L1 levels on tumor cells|Biomathematical modeling of tumor growth|Progression free survival (PFS)","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18251|NCI-2018-02764|R01CA236500","September 26, 2019","January 22, 2022","January 22, 2022","July 1, 2019",,"April 16, 2020","City of Hope Medical Center, Duarte, California, United States",,"https://ClinicalTrials.gov/show/NCT04003649"
14,"NCT04013672","Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence",,"Recruiting","No Results Available","Recurrent Glioblastoma","Drug: Pembrolizumab|Drug: SurVaxM|Drug: Sargramostim|Drug: Montanide ISA 51","Progression free survival (PFS)|Safety and tolerability of Pembrolizumab and SurVaxM as measure by CTCAE v 5 grading as per NCI","Manmeet Ahluwalia, MD|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE6318","March 16, 2020","December 31, 2020","December 31, 2021","July 10, 2019",,"March 18, 2020","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04013672"
15,"NCT03750071","VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma",,"Recruiting","No Results Available","Recurrent Glioblastoma","Biological: VXM01|Biological: Avelumab","Treatment-emerging adverse events (safety and tolerability of VXM01 in combination with avelumab)|Clinical response as assessed by time to progression (TTP)|Clinical response as assessed by progression free survival (PFS)|Clinical response as assessed by recurrence-free survival after re-operation (RFS)|Clinical response as assessed by Overall Survival (OS)|Best overall response (OR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)|Duration of Response (DoR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)","Vaximm GmbH|Merck KGaA, Darmstadt, Germany|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VXM01-AVE-04-INT","November 21, 2018","December 31, 2020","December 31, 2020","November 21, 2018",,"July 19, 2019","CHU La Timone, Marseille, France|Neurology Clinic and National Center for Tumor Diseases, Heidelberg, Germany|Neurology Clinic, Mannheim, Germany|UMC, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03750071"
16,"NCT03732352","18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma",,"Recruiting","No Results Available","EGFR Gene Amplification|EGFR Gene Mutation|Glioblastoma|Recurrent Glioblastoma|Supratentorial Glioblastoma|TP53 wt Allele","Other: Fludeoxyglucose F-18|Drug: Osimertinib|Procedure: Positron Emission Tomography","Intrapatient variance of tumor fludeoxyglucose F-18 (FDG) uptake as determined by a double baseline FDG positron emission tomography (PET) prior to osimertinib exposure|Change in FDG uptake in tumor after short course exposure to osimertinib|Incidence and severity of adverse events (AEs) assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03|Percentage of participants surviving 6 months from the start of study treatment without progression of disease determined by progression free survival (PFS) according to Response Assessment in Neuro-oncology criteria|Correlation between the reduction in glucose uptake and 6 months PFS|Concentrations of osimertinib and metabolites AZ5104 and AZ7550 in post-dosing plasma samples.","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Translational Research in Oncology|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-001000|NCI-2018-02010|P30CA016042","November 28, 2018","November 1, 2020","November 1, 2021","November 6, 2018",,"November 12, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03732352"
17,"NCT04277221","ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)",,"Recruiting","No Results Available","Glioblastoma Multiforme","Biological: Autologous Dendritic Cell/Tumor Antigen, ADCTA","Overall Survival (OS)|Progression-free Survival (PFS)|Progression-free Survival at 6 months (PFS6)|1 and 2-year Survival Rate","Safe Save Medical Cell Sciences & Technology Co.,Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADCTA-SSI-G1","September 19, 2019","December 31, 2022","December 31, 2022","February 20, 2020",,"March 17, 2020","Chang Gung Memorial Hospital, Chiayi branch, Chiayi City, Taiwan|Chang Gung Memorial Hospital, Kaohsiung branch, Kaohsiung City, Taiwan|Chang Gung Memorial Hospital, Keelung branch, Keelung, Taiwan|Taichung Veterans General Hospital, Taichung City, Taiwan|National Cheng Kung University Hospital, Tainan City, Taiwan|Chi Mei Medical Center, Tainan City, Taiwan|Chang Gung Memorial Hospital, Linkou branch, Taoyuan City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04277221"
18,"NCT03539731","[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers",,"Recruiting","No Results Available","Healthy Subject|Intracranial Neoplasm|Recurrent Glioblastoma","Drug: Fluorine F 18 DASA-23|Procedure: Positron Emission Tomography","Change in [18F]DASA-23 PET scan signal in patients with suspected recurrent glioblastoma|Sensitivity of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Specificity of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Accuracy of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Progression-free survival in patients with suspected recurrent glioblastoma|Overall survival in patients with suspected recurrent glioblastoma","Sanjiv Sam Gambhir|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BRN0038|NCI-2018-00826|44597","April 23, 2018","April 23, 2020","April 23, 2020","May 29, 2018",,"October 10, 2018","Stanford University, School of Medicine, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT03539731"
19,"NCT03107780","Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer",,"Recruiting","No Results Available","Glioblastoma|Gliosarcoma|Recurrent Glioblastoma","Other: Laboratory Biomarker Analysis|Drug: MDM2 Inhibitor KRT-232|Other: Pharmacological Study|Radiation: Radiation Therapy","Pharmacokinetics (PK) parameters with target inter-tumor drug concentration at >= 25 nm (Part 1)|Maximum tolerated dose (MTD) of MDM2 inhibitor AMG 232 (KRT-232) when combined with concomitant radiation therapy (Part 2)|Incidence of adverse events (Part 1)|Variability of MDM2 inhibitor AMG 232 (KRT-232) concentration in tumor enhancing versus (vs.) infiltrative tissue (Part 1)|p21 elevation in tissue (Part 1)|Incidence of adverse events (Part 2)|MIC-1 elevation in serum (Part 2)|MDM2 inhibitor AMG 232 (KRT-232) exposure (Part 2)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","86","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2017-00568|ABTC-1604|UM1CA137443","February 26, 2018","June 30, 2020","June 30, 2020","April 11, 2017",,"May 5, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03107780"
20,"NCT02981940","A Study of Abemaciclib in Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Drug: Abemaciclib|Procedure: Surgery","Intratumoral abemaciclib concentration|6-Month Progression Free Survival (PFS6)|pRB expression level of tumor tissue|Incidence of Treatment-Emergent Adverse Events|Area under the plasma concentration versus time curve (AUC)|Peak Plasma Concentration (Cmax)|Radiographic Response Rate|Median Progression Free Survival|Overall Survival","Dana-Farber Cancer Institute|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-383","February 9, 2017","April 2020","April 2022","December 5, 2016",,"March 23, 2020","University of California Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|UT, M.D. Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02981940"
21,"NCT03643549","Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (BORTEM-17)","BORTEM-17","Recruiting","No Results Available","Glioblastoma","Drug: Bortezomib and Temozolomide Phase IB|Drug: Bortezomib and Temozolomide Phase II","Bortezomib-Temozolomide Maximum tolerated dose|Overall survival|Progression free survival|Time to progression|Biomarkers of treatment response|Tumour responses|Clinical response","Haukeland University Hospital|Oslo University Hospital|St. Olavs Hospital|University Hospital of North Norway|University of Bergen|University of Bonn|University of Oslo","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","63","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BORTEM-17","August 30, 2018","December 31, 2022","August 30, 2023","August 22, 2018",,"February 12, 2020","Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT03643549"
22,"NCT03618667","GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification",,"Recruiting","No Results Available","Glioblastoma, Adult|EGFR Amplification","Drug: GC1118","Progression-free survival|overall survival|overall response rate|Exploration of predictive/prognostic biomarkers","Samsung Medical Center","All","19 Years and older   (Adult, Older Adult)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMC2017-06-111","April 30, 2018","January 21, 2020","July 21, 2020","August 7, 2018",,"August 7, 2018","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03618667"
23,"NCT03890952","Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma",,"Recruiting","No Results Available","Recurrent Adult Brain Tumor","Drug: Nivolumab|Drug: Bevacizumab","Number of indels as determined using mRNA sequencing|Progression-Free Survival (PFS)","Ulrik Lassen|Herlev Hospital|University of Copenhagen|Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CA209-9UP|2017-003925-13","October 1, 2018","February 1, 2022","August 1, 2022","March 26, 2019",,"March 26, 2019","Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03890952"
24,"NCT03965494","AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery",,"Recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: BGB 324 (before surgery)|Drug: BGB 324 (after surgery)","Proportion of patients who achieve a drug concentration at >= 1.0 uM level in contrast enhancing tumor tissue|Change in AXL expression level|Pharmacokinetics as measured by plasma maximum concentration (Cmax) (ug/mL)|Pharmacokinetics as measured by plasma minimum concentration (Cmin) (ug/mL)|Pharmacokinetics as measured by area under the curve (AUC) (ug/mL*hr)|Toxicity as assessed by number of participants experiencing of adverse events|Overall survival|Progression-free survival","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|BerGenBio ASA","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","20","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABTC-1701|IRB00184546|UM1CA137443","January 2, 2020","December 1, 2022","December 1, 2023","May 29, 2019",,"March 30, 2020","Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03965494"
25,"NCT03341806","Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|GBM","Drug: Avelumab|Combination Product: MRI-guided LITT therapy","Dose Limiting Toxicity level|Objective response rate (ORR)|Progression-free survival|Overall response rate","Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 17-1866","June 28, 2018","September 2020","February 2021","November 14, 2017",,"September 20, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03341806"
26,"NCT03661723","Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Drug: Pembrolizumab|Drug: Bevacizumab|Radiation: Re-irradiation","Objective response rate|Overall survival rate|Progression free survival|Duration of response|Safety & Tolerability: toxicities and grades experienced by participants","Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-277|3475-787","September 28, 2018","August 31, 2020","February 28, 2021","September 7, 2018",,"June 18, 2019","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Columbia University / Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03661723"
27,"NCT02715297","Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma","GlioCave/NOA17","Recruiting","No Results Available","Glioblastoma","Radiation: SRT to the resection cavity","Progression free survival (PFS) at 12 months|Overall survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Quality of Life questionnaire|Neurocognitive function","Technische Universität München|Helmholtz Zentrum München","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","162","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RadOnc MRI TUM - 1","February 2016","February 2023","February 2023","March 22, 2016",,"March 10, 2020","Dept. Radiation Oncology, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT02715297"
28,"NCT02669173","Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Drug: Capecitabine|Drug: Bevacizumab","Change of concentration in circulating MDSCs after treatment with low dose capecitabine|Concentration of MDSCs in resected glioblastoma after treatment with low dose capecitabine|Concentration of T-regulatory cells after treatment with low dose capecitabine|Number of participants with adverse events relating to treatment with low-dose capecitabine alone as assessed by CTCAE v4.0|Number of participants with adverse events relating to treatment with low-dose capecitabine combined with bevacizumab as assessed by CTCAE v4.0","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE7315","April 20, 2016","June 2020","November 2020","February 1, 2016",,"January 28, 2020","Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02669173"
29,"NCT02709226","Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma",,"Recruiting","No Results Available","Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme|Gliosarcoma","Radiation: Radiation","To determine maximum tolerated re-irradiation dose (MTD)|To determine progression free survival and overall survival|To determine late toxicity secondary to re-irradiation|To determine QOL and impact on neurocognition in the settingof re-irradiation of recurrent glioblastoma","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","NIH","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160081|16-C-0081","June 15, 2016","October 30, 2020","October 30, 2025","March 16, 2016",,"March 26, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02709226"
30,"NCT03233152","Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma","GlitIpNi","Recruiting","No Results Available","Glioblastoma","Drug: Ipilimumab (YervoyTM, 50 mg/10 mL solution)|Drug: Nivolumab (OpdivoTM, 40 mg/4mL solution)","Progression-free survival (PFS)|Overall Survival (OS)","Universitair Ziekenhuis Brussel","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-BN-002","November 17, 2016","November 17, 2019","November 17, 2019","July 28, 2017",,"January 23, 2019","Universitair Ziekenhuis Brussel, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT03233152"
31,"NCT04074785","Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6",,"Recruiting","No Results Available","GBM|Glioblastoma|Brain Tumor|Brain Tumor, Recurrent","Drug: Abemaciclib|Drug: Bevacizumab","Safety|Overall Survival|Progression Free Survival","University of Texas Southwestern Medical Center","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCCC-06319; STU-2019-1214","December 13, 2019","October 24, 2021","October 24, 2022","August 30, 2019",,"January 7, 2020","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04074785"
32,"NCT02663271","TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma|Malignant Glioma|GBM","Drug: Bevacizumab|Device: Optune|Other: Brain MRI|Other: Quality of Life Questionnaires","Progression-free survival between the groups|Number of adverse events|Karnofsky Performance Scale|Mini-Mental Status Exam|Response Assessment in Neuro-Oncology (RANO) Measurement Form","University of Florida|NovoCure Ltd.","All","22 Years and older   (Adult, Older Adult)","Phase 2","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201600074|OCR14874","August 2016","March 15, 2021","March 15, 2021","January 26, 2016",,"March 2, 2020","University of Florida, Gainesville, Florida, United States|Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02663271"
33,"NCT03294486","Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients","ONCOVIRAC","Recruiting","No Results Available","Glioblastoma|Brain Cancer","Drug: Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)","Number of Participant with Dose Limiting Toxicities defined as Any of the following treatment-related adverse events (AEs) is evaluated and reported from Day 1 through Day 26; as assessed by NCI-CTCAE, version 4.03|Number of patients without documented tumor progression at 6 months from date of first TG6002 infusion according to Response Assessment Neuro-Oncology Criteria (Wen et al., 2010, JCO, PMID:20231676)|TG6002 recommended dose prior to the Phase 2a part of the study (RP2D) in combination with 5-FC (Maximum Plasma Concentration [Cmax])|Overall Survival (OS)|Relative quantification of circulating viral DNA|Blood pharmacokinetics of 5-FC|Blood pharmacokinetics of 5-Fluorouraril (5-FU)|Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL)|Viral shedding in saliva, urine and feces|Humoral response|Isolation of peripheral blood mononuclear cells (PBMC);|Metabolic Response|Safety and tolerability : Incidence of Treatment; evaluation of treatement-releated adverse events","Assistance Publique - Hôpitaux de Paris|Transgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","78","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P150936|2015-004452-21","October 12, 2017","May 2019","September 2021","September 27, 2017",,"November 6, 2017","Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT03294486"
34,"NCT03025893","A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme","STELLAR","Recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma, Adult|Glioblastoma|Recurrent Brain Tumor|GBM","Drug: Sunitinib|Drug: Lomustine","Six-month progression-free survival (PFS-6)|Overall survival (OS)|Objective radiological response rate|Adverse events (AEs)|Health-related quality of life (HRQoL)|Blood markers (TEP: tumor educated platelets, and miRNA)|MGMT promoter methylation status","VU University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016.221","August 31, 2018","January 2020","January 2020","January 20, 2017",,"August 30, 2019","VU University Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03025893"
35,"NCT01954576","NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme",,"Recruiting","No Results Available","Glioblastoma|Brain Neoplasms","Device: NovoTTF-100A|Procedure: Quality-of-life assessment|Genetic: Laboratory biomarker analysis","ORR (CR + PR + SD) (bevacizumab-naive)|ORR (CR + PR + SD) (bevacizumab-refractory)|Genetic signature of response (CR + PR + SD)|Genetic signature of response (CR + PR) and SD|Progression-free survival in bevacizumab-naïve and bevacizumab-refractory glioblastoma patients|Quality of Life","University of Florida|Washington University School of Medicine|NovoCure Inc.","All","22 Years and older   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201500287|09-27-2013|201306042|OCR14655","October 10, 2013","December 2020","March 2022","October 7, 2013",,"March 2, 2020","University of Florida, Gainesville, Florida, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01954576"
36,"NCT04222309","Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)",,"Recruiting","No Results Available","Glioma|Glioma, Malignant|Glioblastoma|Glioblastoma Multiforme|Glioblastoma Multiforme of Brain|GBM|Brain Cancer","Procedure: Laparoscopically harvested omental free flap","Safety parameter: proportion of patients experiencing rapidly progressive disease as indicated by MRI using RANO Criteria|Safety parameter: proportion of patients experiencing increase in seizures, stroke, and infection|Progression Free Survival (PFS)|Overall Survival (OS)|Percent of screen fails","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-0801","January 6, 2020","January 31, 2022","January 31, 2022","January 9, 2020",,"January 9, 2020","Lenox Hill Brain Tumor Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04222309"
37,"NCT02761070","Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III","RE-GEND","Recruiting","No Results Available","Glioblastoma|Recurrence|Progression","Drug: Temozolomide|Drug: Bevacizumab","Overall survival|Progression-free survival (PFS)|6-month progression-free survival (6m-PFS)|Complete response rate|Response rate|Adverse events|Serious adverse events|Progression-free survival (PFS) from bevacizumab (BEV) initiation|6-month progression-free survival (6m-PFS) after initiation of bevacizumab (BEV) (Experimental Arm Only)|Overall survival after initiation of bevacizumab (BEV)","Kyorin University|Japan Clinical Oncology Group","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JCOG1308C","July 11, 2016","July 10, 2022","July 10, 2023","May 4, 2016",,"February 27, 2019","Nagoya University Hospital, Nagoya, Aichi, Japan|Fujita Health University Hospital, Toyoake, Aichi, Japan|Hirosaki University School of Medicine, Hirosaki, Aomori, Japan|Ehime University Graduate School of Medicine, Shizukawa, Ehime, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Kobe University Hospital, Kobe, Hyougo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Iwate Medical University, Morioka, Iwate, Japan|Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan|Kansai Medical University, Hirakata, Osaka, Japan|Osaka University Graduate School of Medicine, Suita, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Dokkyo Medical University, Shimotsuge, Tochigi, Japan|Tokyo Medical And Dental University, Medical Hospital, Bunkyō-Ku, Tokyo, Japan|Chiba University Hospital, Chiba, Japan|Kusyu University Graduate School of Medical Sciences, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan|Kitasato University School of Medicine, Kanagawa, Japan|Kumamoto University Hospital, Kumamoto, Japan|Kyoto University Graduate School of Medicine, Kyoto, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka International Cancer Institute, Osaka, Japan|Nakamura Memorial Hospital, Sapporo, Japan|Hokkaido University Graduate School of Medicine, Sapporo, Japan|Shizuoka Canser Center Hospital, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|The University of Tokyo Hospital, Tokyo, Japan|Keio University Hospital, Tokyo, Japan|Nihon University School of Medicine Itabashi Hospital, Tokyo, Japan|Kyorin University Faculty of Medicine, Department of Neurosurgery, Tokyo, Japan|Yamagata University Hospital, Yamagata, Japan",,"https://ClinicalTrials.gov/show/NCT02761070"
38,"NCT03997617","Personalized Functional Profiling in Metastatic Gastrointestinal Cancer or Recurrent Glioblastoma Patients in Luxembourg.",,"Recruiting","No Results Available","Oncology","Diagnostic Test: Personalized Functional Profiling","Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP|Quantity of cells needed for the PFP analysis|Duration of the PFP process for one specific patient|Number of drugs recommended by using the PFP approach|Number of patients for which the treatment recommendation issued by PFP were followed by the investigator","Luxembourg Institute of Health|Integrated Biobank of Luxembourg|Laboratoire National de Santé (Luxembourg)|Centre Hospitalier du Luxembourg|Hopitaux Robert Schuman (Luxembourg)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PFP-001","March 11, 2019","December 1, 2020","March 30, 2021","June 25, 2019",,"May 1, 2020","Centre hospitalier de Luxembourg, Luxembourg, Luxembourg|Hôpitaux Robert Schmuan, Luxembourg, Luxembourg",,"https://ClinicalTrials.gov/show/NCT03997617"
39,"NCT02765165","Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)",,"Recruiting","No Results Available","Solid Tumors (Phase 1)|Relapsed/Recurrent GBM (Phase 2)","Drug: USL311|Drug: Lomustine","Phase 1: Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)|Phase 2: Percentage progression free survival (PFS) at 6 months (PFS-6m)|Phase 1 and Phase 2: Treatment-related adverse events as assessed by CTCAE v4.03|Phase 1 and Phase 2: Overall survival (OS)|Phase 1 and Phase 2: Progression free survival (PFS)|Phase 1 and Phase 2: Objective response rate (ORR%)|Phase 1 and Phase 2: Peak concentration (Cmax)|Phase 1 and Phase 2: Time to peak concentration (Tmax)|Phase 1 and Phase 2: Area under the concentration vs time curve (AUC)","Proximagen, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P311-201","April 2016","September 2022",,"May 6, 2016",,"May 10, 2019","Washington University, Saint Louis, Missouri, United States|University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|University of Texas/MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States|UT Health San Antonio Cancer Center, San Antonio, Texas, United States|South Texas Accelerated Research Therapeutics (START) - CIOCC, Madrid, Spain|South Texas Accelerated Research Therapeutics (START) - FJD, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02765165"
40,"NCT02766699","A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)","CerebralEDV","Recruiting","No Results Available","Glioblastoma|Astrocytoma, Grade IV","Drug: EGFR(V)-EDV-Dox","Safety outcome measures|Efficacy outcome measure|Identification of a recommended Phase 2 dose (RP2D) of EGFR(V)-EDV-Dox in subjects with recurrent GBM|Overall survival outcome measure.","Engeneic Pty Limited|Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENG7","October 25, 2016","December 2019","June 2020","May 10, 2016",,"August 29, 2019","John Hopkins Hospital, Baltimore, Maryland, United States|Lenox Hill Hospital, Northwell Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02766699"
41,"NCT03782415","Study to Evaluate Ibudilast and TMZ Combo Treatment in Recurrent GBM",,"Recruiting","No Results Available","Glioblastoma|Recurrent Glioblastoma|GBM|Recurrent GBM","Drug: MN-166|Drug: Temozolomide","Determine Progression-free survival pf patients at 6 months|Safety Evaluation (Adverse events or discontinuation due to Dose limiting toxicities)|Maximum tolerated dose determination","MediciNova","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","MN-166-GBM-1201","December 29, 2018","December 2021","December 2022","December 20, 2018",,"January 22, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03782415"
42,"NCT02394626","Surgery for Recurrent Glioblastoma","RESURGE","Recruiting","No Results Available","Glioblastoma","Procedure: Surgery followed by adjuvant second-line therapy|Procedure: Second-line therapy alone","Overall survival from the date of inclusion|Recruitment rate for all screened patients|Progression-free survival|Morbidity of surgery|Total number of days spent at home after recurrence|Total number of days spent outside home after recurrence","University Hospital Inselspital, Berne|European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","368/14","May 2015","October 2021","October 2021","March 20, 2015",,"March 25, 2020","Universitätsklinikum Innsbruck, Innsbruck, Austria|Helios Klinikum Erfurt, Erfurt, Germany|Department of Neurosurgery, Universitätsklinikum Frankfurt, Frankfurt, Germany|Dep. of Neurosurgery, Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Gießen und Marburg, Giessen, Germany|Department of Neurosurgery, Universitätsklinikum Köln, Köln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Münster, Münster, Germany|Department of Neurosurgery, Hospital of Larissa & General Hospital of Larissa, Larissa, Greece|Department of Neurosurgery, AHEPA University Hospital, Thessaloníki, Greece|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy|Department of Neurosurgery, Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria, Lisboa, Portugal|Department of Neurosurgery, Spitalul Clinic De Urgență ""Bagdasar-Arseni"", Bucharest, Romania|Kantonsspital Aarau, Aarau, Switzerland|Universitätsspital Basel, Basel, Switzerland|Dep. of Neurosurgery, Bern University Hospital, Bern, Switzerland|Dep. of Neurosurger, Hôpitaux Universitaires de Genève, Geneva, Switzerland|Dep. of Neurosurgery, Centre hospitalier universitaire vaudois, Lausanne, Switzerland|Ospedale Regionale di Lugano, Lugano, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Department of Neurosurgery, Kantonsspital St. Gallen, Saint Gallen, Switzerland|Dep. of Neurosurgery, University Hospital of Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02394626"
43,"NCT02062827","Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma","M032-HSV-1","Recruiting","No Results Available","Recurrent Glioblastoma Multiforme|Progressive Glioblastoma Multiforme|Anaplastic Astrocytoma or Gliosarcoma","Biological: M032 (NSC 733972)","Highest safe dose/MTD (maximum tolerated dose) or maximally planned dose if no dose-limiting toxicity observed|Time to progression assessment|The time of survival assessment|The time of biologic assessment","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UAB-1317","September 2014","September 2021","September 2023","February 14, 2014",,"April 7, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT02062827"
44,"NCT02678975","Disulfiram in Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioma|Glioblastoma","Drug: Disulfiram|Dietary Supplement: Copper|Drug: Alkylating Agents","Survival 6 mo|Progression free survival|Survival 12 and 24 mo|Median overall survival|Health related quality of life|Volumetric tumor assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Sahlgrenska University Hospital, Sweden|St. Olavs Hospital|Lund University Hospital|Karolinska University Hospital|University Hospital, Linkoeping|Region Örebro County|Ryhov County Hospital|Uppsala University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","no ID yet","January 2017","December 2021","September 2023","February 10, 2016",,"April 4, 2019","Cancer Clinic, St.Olavs University Hospital, Trondheim, Norway|Dept. of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden|Ryhov County Hospital, Jönköping, Sweden|Linköping University Hospital, Linkoping, Sweden|Lund University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Sweden|Örebro University Hospital, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT02678975"
45,"NCT03970447","A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","GBM AGILE","Recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Lomustine|Drug: Regorafenib|Radiation: Radiation","Overall Survival (OS)|Progression-free survival (PFS)|Tumor Response|Duration of Response (CR + PR)","Global Coalition for Adaptive Research|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","550","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCAR-7213","July 30, 2019","December 2022","December 2022","May 31, 2019",,"May 4, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|LSU Health Sciences Center - New Orleans, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina - Hollings Cancer Center, Charleston, South Carolina, United States|Texas Oncology - Austin, Austin, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States|Froedtert Hospital/Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03970447"
46,"NCT03027388","Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",,"Recruiting","No Results Available","Astrocytoma, Grades II, III and IV|Glioblastoma Multiforme|Giant Cell Glioblastoma|Glioma|Oligodendrogliomas","Drug: LB-100","Drug Level in tumor tissue|Plasma concentration and calculated LB100|Concentration of LG100 and its major metabolite LB100 in glioblastoma tumor tissue|Relationship between drug concentration at the site of action and the resulting effect and the presence of correlation to identify predictive markers.|Changes in phospho-protein expression in circulating PBMC","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","20","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","170037|17-C-0037","May 9, 2019","August 30, 2021","August 30, 2021","January 23, 2017",,"April 20, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03027388"
47,"NCT03744026","Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9","SC9-GBM-01","Recruiting","No Results Available","Glioblastoma, Adult","Device: SonoCloud-9|Drug: Carboplatin","Dose limiting toxicity (DLT) of number of activated ultrasound beams|Blood-Brain Barrier (BBB) opening","CarThera","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC9-GBM-01","February 18, 2019","February 20, 2020","July 1, 2020","November 16, 2018",,"January 27, 2020","CHU, Angers, France|Hôpital Neurologique Pierre Wertheimer, Bron, France|Hôpital de La Timone, Marseille, France|Hôpital de la Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT03744026"
48,"NCT03596086","HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM",,"Recruiting","No Results Available","Glioblastoma Multiforme|Astrocytoma, Grade III","Drug: ADV/HSV-tk (gene therapy)","Survival in months from Study drug administration (Day 0)|Progression Free Survival assessments will be done every 6-8 weeks for 1st year thereafter every 12-14 weeks until disease progression or death","David Baskin MD|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","62","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00016414","December 11, 2017","December 30, 2023","December 30, 2025","July 23, 2018",,"August 28, 2019","Houston Methodist Neurological Institute, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03596086"
49,"NCT04214392","Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma",,"Recruiting","No Results Available","Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma","Biological: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes","Dose limiting toxicity (DLT)|Chimeric antigen receptor (CAR) T cell|Endogenous T cell|Cytokine levels in TCF, PB and CSF|Progression free survival time|Disease response|Overall survival (OS)|CAR T cells detected in tumor tissue|Chlorotoxin-targeted antigen expression levels in tumor tissue|Biomathematical modeling of tumor growth","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19309|NCI-2019-08393","February 26, 2020","February 6, 2023","February 6, 2023","January 2, 2020",,"May 1, 2020","City of Hope Medical Center, Duarte, California, United States",,"https://ClinicalTrials.gov/show/NCT04214392"
50,"NCT02869243","A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients",,"Recruiting","No Results Available","Glioblastoma","Drug: hrBMP4","DLTs|Tumor response|Quality of Life|Maximum observed plasma concentration of BMP4 (Cmax)|Lowest concentration of BMP4 in the blood (Ctrough)|Area under the curve (AUC∞)|Central and peripheral volumes of distribution (Vd)|Clearance|Half-life (t1/2)","Stemgen|ORION Clinical Services","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","hrBMP4-001","July 18, 2017","January 25, 2019","August 5, 2019","August 16, 2016",,"November 29, 2018","Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Istituto Neurologico Carlo Besta, Milano, Italy|VU University Medical Center, Amsterdam, Netherlands|Erasmus University Medical Center, Department of Neurosurgery, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02869243"
51,"NCT03463733","Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)","HUTMZ","Recruiting","No Results Available","Glioma|Glioblastoma","Drug: Hydroxyurea|Drug: Temozolomide","Maximal tolerated dose (MTD) hydroxyurea in combination with dose intense temozolomide","M.E. van Linde|Massachusetts General Hospital|VU University Medical Center","All","Child, Adult, Older Adult","Phase 1","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro-16/11","March 2, 2018","June 1, 2021","June 1, 2022","March 13, 2018",,"August 29, 2019","VU University Medical Center, Amsterdam, Noord-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03463733"
52,"NCT03119064","BrUOG 329 GBM Onyvide With TMZ","329","Recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma|GBM","Drug: Nanoliposomal Irinotecan|Drug: Temozolomide","MTD|Response|PFS|Toxicities","Heinrich Elinzano, MD|Merrimack Pharmaceuticals|Rhode Island Hospital|Brown University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BrUOG 329","November 30, 2017","July 2019","July 2020","April 18, 2017",,"January 7, 2019","Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT03119064"
53,"NCT02525692","Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma",,"Recruiting","No Results Available","Glioblastoma|Diffuse Midline Glioma|H3 K27M Glioma|Thalamic Glioma|Infratentorial Glioma|Basal Ganglia Glioma","Drug: ONC201","Progression-free survival","Oncoceutics, Inc.","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONC006","January 2016","December 2020","December 2020","August 17, 2015",,"January 6, 2020","University of California, Los Angeles, Los Angeles, California, United States|Miami Cancer Institute, Miami, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02525692"
54,"NCT03914742","BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations",,"Recruiting","No Results Available","IDH1 Mutation|IDH2 Mutation|Recurrent Glioblastoma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma","Drug: PARP Inhibitor BGB-290|Drug: Temozolomide|Procedure: Therapeutic Conventional Surgery","Phase I: Maximum tolerated dose (MTD)|Phase I: Percentage of participants with adverse events|Phase II: Tumor radiographic response|Phase II: Progression-free survival (PFS)|Phase II: Overall survival (OS)|Duration of response|Percentage of participants with serious or life-threatening adverse events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|BeiGene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","100","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABTC-1801|UM1CA137443","January 3, 2020","April 2022","July 2023","April 16, 2019",,"March 16, 2020","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Yale University, New Haven, Connecticut, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03914742"
55,"NCT03896568","Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma",,"Recruiting","No Results Available","IDH1 wt Allele|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma","Biological: Oncolytic Adenovirus Ad5-DNX-2401|Procedure: Therapeutic Conventional Surgery","Maximum-tolerated dose (MTD)|Incidence of adverse events (AEs)|Tumor response|Time to progression|Virus replication in tumor|Virus shedding|Immunogenicity based on adenoviral (AdV) antibodies","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0953|NCI-2019-01195|P30CA016672","February 12, 2019","February 28, 2020","February 28, 2020","April 1, 2019",,"November 5, 2019","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03896568"
56,"NCT01904123","STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm in the Brain|Metastatic Melanoma|Recurrent Brain Neoplasm|Recurrent Glioblastoma|Recurrent Malignant Glioma","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: STAT3 Inhibitor WP1066","Maximum tolerated dose (MTD) of JAK2 inhibitor WP1066, defined as the dose level at which 0/6 or 1/6 patients experience a dose limiting toxicity (DLT) with at least 2 patients experiencing DLT at the next higher dose level|Incidence of adverse events assessed using NCI CTC|Pharmacokinetic analysis of the in vivo bioavailability of JAK2 inhibitor WP1066|Proportion of patients reaching complete response or partial response|Duration of response|Overall survival|Progression free survival|The proportion of patients who develop additional melanoma metastatic lesions|Change in regulatory T cell numbers|Change in the number of peripheral blood mononuclear cells expressing phosphorylated STAT3","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0358|NCI-2015-00163|P30CA016672|P50CA127001|P50CA093459","July 13, 2018","July 31, 2021","July 31, 2021","July 22, 2013",,"December 12, 2019","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01904123"
57,"NCT02704858","Safety and Efficacy Study in Recurrent Grade IV Glioma",,"Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Perillyl alcohol","Phase 1 Primary Outcome: Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment|Phase 2 Primary Outcome: Number of Participants Who Are Alive Each Month For 6 Months|Phase 2 Primary Outcome: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related To Treatment","Neonc Technologies, Inc.|ClinDatrix, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","43","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NEO100-01","April 2016","June 2020","October 2020","March 10, 2016",,"August 28, 2018","University of Southern California, Los Angeles, California, United States|Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Wisconsin Hospital and Clinic, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02704858"
58,"NCT03277638","Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)",,"Recruiting","No Results Available","Glioblastoma, Adult","Drug: Pembrolizumab at 7 days prior|Drug: Pembrolizumab at 14 days post|Drug: Pembrolizumab at 35 days post|Procedure: Laser Interstitial Thermotherapy","Phase I Objective: Optimal timing of LITT with pembrolizumab|Phase II Objective: Tumor Response|Progression free survival|overall survival|The proportion of patients who achieve progression free survival at 6 months (PFS6)|The proportion of patients who achieve progression free survival at 12 months (PFS12)|The proportion of patients who achieve progression free survival at 24 months (PFS24)","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE3316","November 29, 2017","May 2020","July 2020","September 11, 2017",,"January 3, 2020","University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03277638"
59,"NCT04044937","Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors",,"Recruiting","No Results Available","Intracranial Neoplasm|Low Grade Glioma|Recurrent Glioblastoma|Recurrent World Health Organization (WHO) Grade II Glioma|Recurrent WHO Grade III Glioma","Drug: F-18 Fluoroethyltyrosine (FET)|Procedure: Positron Emission Tomography (PET)","Binary characterization of study as positive/negative for recurrence disease in three groups of patients with intracranial neoplasms with concern for recurrence or progression on conventional imaging (Population 1)|Binary characterization of study as positive/negative for high grade glial neoplasms in patients prior to primary treatment with planned biopsy or surgical resection (Population 2)|Intracranial lesion standardized uptake values (SUV): SUVvolume, SUVmax and SUVpeak at each imaging time point.|Binary characterization of follow-up imaging as positive/negative for tumor recurrence|Misclassification rate, sensitivity, specificity, positive predictive value, negative predictive value and accuracy for FET PET in the evaluation of recurrence of low-grade gliomas.","Thomas Hope|University of California, San Francisco","All","3 Years and older   (Child, Adult, Older Adult)","Phase 2","199","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","171022|NCI-2018-01875","October 29, 2018","August 1, 2021","August 1, 2022","August 5, 2019",,"February 17, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04044937"
60,"NCT03893487","Fimepinostat in Treating Brain Tumors in Children and Young Adults","PNOC016","Recruiting","No Results Available","Diffuse Intrinsic Pontine Glioma|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent Medulloblastoma","Drug: Fimepinostat|Procedure: Therapeutic Conventional Surgery","Penetration of fimepinostat across the blood brain barrier (BBB)","Sabine Mueller, MD, PhD|Pacific Pediatric Neuro-Oncology Consortium|Cannonball Kids' Cancer Foundation|Curis, Inc.|University of California, San Francisco","All","3 Years to 39 Years   (Child, Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18086|PNOC016","August 7, 2019","June 2022","June 2027","March 28, 2019",,"February 25, 2020","Rady Children's Hospital, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Florida, Gainesville, Florida, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University in St Louis, Saint Louis, Missouri, United States|The University Children's Hospital in Zurich, Zürich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03893487"
61,"NCT02661282","Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma",,"Recruiting","No Results Available","Cytomegalovirus Positive|Glioblastoma|Gliosarcoma|Malignant Glioma|Recurrent Brain Neoplasm|Recurrent Glioblastoma","Biological: Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes|Other: Laboratory Biomarker Analysis|Drug: Temozolomide|Procedure: Therapeutic Conventional Surgery","Maximum feasible dose (MFD) or maximum tolerated dose (MTD) (recurrent glioblastoma cohort)|Immunological effects in tumor tissue (recurrent glioblastoma cohort)|Progression free survival (PFS) (recurrent glioblastoma cohort)|Overall survival (OS) (newly diagnosed glioblastoma cohort)|Time to progression (recurrent glioblastoma cohort)|Objective response rate (ORR) (newly diagnosed glioblastoma cohort)|Median duration of response (newly diagnosed glioblastoma cohort)|Progression free survival (PFS) (newly diagnosed glioblastoma cohort)|Incidence of toxicity (newly diagnosed glioblastoma cohort)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","54","Other|NIH","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0899|NCI-2016-00183|P30CA016672","June 1, 2016","June 1, 2020","June 1, 2020","January 22, 2016",,"January 29, 2020","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02661282"
62,"NCT02192359","Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas",,"Recruiting","No Results Available","Recurrent Anaplastic Astrocytoma|Recurrent Anaplastic Oligoastrocytoma|Recurrent Anaplastic Oligodendroglioma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma|Recurrent WHO Grade III Glioma","Biological: Carboxylesterase-expressing Allogeneic Neural Stem Cells|Drug: Irinotecan|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Incidence of dose limiting toxicities (DLTs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of all attributable toxicities graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Pharmacokinetics parameters, including maximum concentration and area under the curve of irinotecan and SN-38 in dialysate and plasma|Development of neural stem cells (NSC) immunogenicity after first and repeat exposures|Clinical benefit, defined by tumor response based on magnetic resonance imaging (MRI) results|Fate of the neural stem cells (NSCs), defined by NSC persistence","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 1","53","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14108|NCI-2014-01463|P30CA033572|R01CA198076","March 7, 2016","March 7, 2021","July 7, 2021","July 16, 2014",,"March 20, 2020","City of Hope Medical Center, Duarte, California, United States",,"https://ClinicalTrials.gov/show/NCT02192359"
63,"NCT03749187","BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","PNOC017","Recruiting","No Results Available","Glioblastoma|IDH1 Gene Mutation|IDH2 Gene Mutation|Low Grade Glioma|Malignant Glioma|Recurrent Glioblastoma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma|WHO Grade II Glioma|WHO Grade III Glioma","Drug: PARP Inhibitor BGB-290|Drug: Temozolomide","Summary of Dose Limiting Toxicities Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0","University of California, San Francisco|BeiGene USA, Inc.|Pacific Pediatric Neuro-Oncology Consortium","All","13 Years to 25 Years   (Child, Adult)","Phase 1","78","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18083|NCI-2018-02345|PNOC017","April 3, 2019","June 2022","July 2027","November 21, 2018",,"March 2, 2020","Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03749187"
64,"NCT02717962","Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting",,"Recruiting","No Results Available","Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer","Drug: VAL-083, Dianhydrogalactitol","Overall Survival|Estimate Progression-free Survival|Estimate Median Progression-Free Survival|Estimate Median Overall Survival|Estimate Overall Response Rate|Estimate Duration of Response|Safety evaluation of VAL-083 in patients|Quality of Life|Plasma Pharmacokinetics","DelMar Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","107","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DLM-16-001","January 20, 2017","September 2020","June 2021","March 24, 2016",,"March 17, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02717962"
65,"NCT01466686","Low Dose Radiation Therapy for Glioblastoma Multiforme",,"Recruiting","No Results Available","High Grade Glioma","Radiation: Low Dose Fractionated Radiation Therapy (LDFRT)|Drug: Temozolomide","Response Rate|Time to Progression|Overall Survival Rate|Hematologic Toxicity|Radiation-Associated Long-Term Toxicity","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J11120|NA_00065863","September 2012","September 2021","September 2022","November 8, 2011",,"December 5, 2019","Sibley Memorial Hospital, Washington, District of Columbia, United States|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01466686"
66,"NCT03743662","Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Radiation: Re-irradiation (RT)|Drug: Bevacizumab|Drug: Nivolumab|Procedure: Re-resection","Overall survival|6 month progression-free survival|Median progression-free survival|Objective response rate","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","94","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-400","November 12, 2018","November 2021","November 2021","November 16, 2018",,"March 10, 2020","Miami Cancer Institute Baptist Health South Florida, Miami, Florida, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03743662"
67,"NCT02626364","Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification",,"Recruiting","No Results Available","Recurrent/Refractory Glioblastoma","Drug: crenolanib","Progression-free survival at 6 months|Overall response rate by RANO criteria|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Change in symptom burden using The MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)|Overall survival","Arog Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARO-015","April 2016","April 2020","April 2020","December 10, 2015",,"February 17, 2020","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02626364"
68,"NCT03463265","ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma",,"Recruiting","No Results Available","High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma","Drug: ABI-009|Drug: Bevacizumab|Drug: Temozolomide|Drug: Lomustine|Radiation: radiation|Drug: Marizomib","objective overall response rate according to RANO 2010 criteria|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|progression free survival|overall survival","Aadi, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBM007","August 1, 2018","December 2020","June 2021","March 13, 2018",,"December 10, 2019","St. Joseph Heritage Healthcare, Fullerton, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT03463265"
69,"NCT03243851","Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma","METT","Recruiting","No Results Available","Glioblastoma","Drug: Temozolomide+Metformin|Drug: Temozolomide+Placebo","Comparison of progression-free survival obtained from progression-free survival curve|Response Rate|Tumor control probability|6 month progression free survival|6 month overall survival|Assessment of the quality of life of cancer patients","Yong-Kil Hong|Saint Vincent's Hospital, Korea|Incheon St.Mary's Hospital|National Cancer Center, Korea|Konkuk University Hospital|Seoul National University Bundang Hospital|Samsung Medical Center|Seoul National University Hospital|Asan Medical Center|Ajou University School of Medicine|Severance Hospital|Chonnam National University Hospital|Seoul St. Mary's Hospital","All","19 Years and older   (Adult, Older Adult)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KNOG-1501","November 21, 2016","December 31, 2019","December 31, 2019","August 9, 2017",,"April 4, 2019","National Cancer Center Korea, Ilsan, Gyeonggi-Do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-Do, Korea, Republic of|Ajou University Hospital, Suwon-si, Gyeonggi-Do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-Do, Korea, Republic of|Incheon St. Mary's Hospital, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Saint Vincent's Hospital, Korea, Suwon-si, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03243851"
70,"NCT03383978","Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma","CAR2BRAIN","Recruiting","No Results Available","Glioblastoma","Biological: NK-92/5.28.z","Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.|Maximum tolerated dose (MTD) or maximum feasible dose (MFD).|Period of detectability of NK-92/5.28.z cells in blood and cerebrospinal fluid (CSF) during the first 24 weeks after NK-92/5.28.z application with qPCR.|Cytokine profile in the blood and the cerebrospinal fluid.|NK-92- and/or CAR 5.28.z-directed immune response.|Objective response rate.|Progression-free survival.|Overall survival.","Johann Wolfgang Goethe University Hospital|DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH|Georg-Speyer-Haus|LOEWE Center for Cell and Gene Therapy","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT 2016-000225-39","December 1, 2017","February 2020","August 2020","December 27, 2017",,"May 16, 2019","Johann W. Goethe University Hospital, Department of Neurosurgery, Frankfurt, Germany|Johann W. Goethe University Hospital, Senckenberg Institute of Neurooncology, Frankfurt, Germany",,"https://ClinicalTrials.gov/show/NCT03383978"
71,"NCT04006119","Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Biological: Ad-RTS-hIL-12|Drug: Veledimex|Drug: Cemiplimab-Rwlc","Safety of intratumoral Ad-RTS-hIL-12 and oral veledimex in combination with cemiplimab-rwlc in subjects with recurrent or progressive glioblastoma.|Efficacy of intratumoral Ad-RTS-hIL-12 and oral veledimex in combination with cemiplimab-rwlc in subjects with recurrent or progressive glioblastoma.|To determine the survival rates at 6, 12, 18 and 24 months|To determine the progression free survival (PFS)|To determine the rate of pseudoprogression (PSP) at 6, 12, 18 and 24 months|To determine the Investigator's assessment of response, including tumor objective response rate (ORR) at 6, 12, 18 and 24 months|To determine the tumor response rates at 6, 12, 18 and 24 months|Changes from baseline in cellular responses elicited by Ad-RTS-hIL-12 and veledimex in combination with cemiplimab-rwlc|Changes from baseline in humoral immune responses elicited by Ad-RTS-hIL-12 and veledimex in combination with cemiplimab-rwlc","Ziopharm","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATI001-204","August 1, 2019","June 2022","August 2022","July 2, 2019",,"February 11, 2020","Cedars Sinai, Los Angeles, California, United States|University of California - San Francisco, San Francisco, California, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Brigham and Women's, Boston, Massachusetts, United States|JFK Medical Center, Edison, New Jersey, United States|NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04006119"
72,"NCT03382977","Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects",,"Recruiting","No Results Available","Glioblastoma Multiforme","Biological: VBI-1901","Dose limiting toxicity (DLT) occurring during Part A of the study and the occurrence of AEs during each treatment cycle in both Part A and Part B of the study|Immunogenicity and optimal vaccine-induced immunity-serum IgG anti-gB antibodies (Part A and B)|Cellular immunity against HCMV gB and pp65 antigens (Part A and B)|Changes in frequencies of myeloid suppressor cells and regulatory T cells (Part A and B)|Progression free survival (PFS) (Part A and B)|Overall survival (OS) (Part A and B)|Median overall survival (Part A and B)|Reduction in steroid use compared to baseline (Part A and B)|Change in quality of life (QOL questionnaire) compared to baseline (Part A and B)|Immunogenicity of the optimal dose of VBI-1901 formulated with either GM-CSF or AS01B adjuvants (Part B).","VBI Vaccines Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","38","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VBI-1901-01","December 6, 2017","October 2020","November 2020","December 26, 2017",,"December 3, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|The Neurological Institute of New York Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03382977"
73,"NCT02942264","Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma",,"Recruiting","No Results Available","Brain Tumor|Astrocytoma|Astroglioma|Glioblastoma|Gliosarcoma","Drug: Zotiraciclib (TG02)|Drug: TMZ","Phase I: maximum tolerated dose (MTD) of Zotiraciclib (TG02) plus TMZ using both the dd and mn TMZ schedules in adult patients with recurrent anaplastic astrocytoma or glioblastoma/gliosarcoma.|Phase II: progression free survival in subjects taking Zotiraciclib (TG02) plus TMZ versus TMZ alone in patients with recurrent WHO grade III or IV astrocytoma.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","152","NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170009|17-C-0009","December 14, 2016","August 2, 2021","August 2, 2023","October 24, 2016",,"January 13, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02942264"
74,"NCT02658981","Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)",,"Recruiting","No Results Available","Glioblastoma|Gliosarcoma|Recurrent Brain Neoplasm","Biological: Anti-LAG-3 Monoclonal Antibody BMS 986016|Biological: Anti-PD-1|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis|Biological: Anti-CD137","Maximum tolerated dose (MTD) of anti-LAG-3 monoclonal antibody BMS-986016 as monotherapy as determined by frequency of toxicity|Maximum tolerated dose (MTD) of anti-CD137 as monotherapy as determined by frequency of toxicity|MTD of Anti-LAG-3 + Anti-PD-1 as determined by frequency of toxicity|MTD of Anti-CD137 + Anti-PD-1 as determined by frequency of toxicity|Overall Survival|Progression-free survival rate|Overall Response, assessed by RANO and iRANO|Overall Response to anti-LAG-3 monoclonal antibody BMS-98601, assessed by RANO and iRANO|Overall Response to anti-CD137 as monotherapy, assessed by RANO and iRANO|Overall Response to Anti-LAG-3 + Anti-PD-1, assessed by RANO and iRANO","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABTC 1501|IRB00095527|UM1CA137443","August 2016","August 2020","February 2022","January 20, 2016",,"March 16, 2020","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02658981"
75,"NCT03834740","A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection",,"Recruiting","No Results Available","Glioblastoma Multiforme|Glioma of Brain","Drug: Ribociclib|Drug: Everolimus","Pharmacokinetic analysis -Total and Unbound Ribociclib and Everolimus AUC (0-24)|Pharmacokinetic analysis - Total and Unbound Ribociclib and Everolimus Median concentration Cmax (0-24)|Pharmacokinetic analysis -Median concentration of Total Ribociclib and Everolimus Tmax|Pharmacokinetic analysis - Total Ribociclib and Everolimus T1/2 (0-24)|Pharmacokinetic analysis - Total and Unbound Ribociclib and Everolimus CL/F (0-24)|Median concentration of ribociclib and everolimus for all patients for unbound plasma, CSF, Unbound NE, Unbound enhancing (2-24H post last dose)|The percentage of pRB positive cells will be quantified in resected post-treatment recurrent tumor tissue compared to baseline (archival primary GBM tumor)|The percentage of pS6 positive cells will be quantified in resected post-treatment recurrent tumor tissue compared to baseline (archival primary GBM tumor)|MTD: highest dose of drug that did not cause a DLT in > 33% of participants|Median progression-free survival (PFS) from time of surgery to date of recurrence in Phase 2 patients|Median Overall Survival (OS) from time of surgery to date of recurrence in Phase 2 patients|Number of Adverse Events|Median concentration of trough plasma concentrations of Total Ribociclib and Total Everolimus in Phase 2","St. Joseph's Hospital and Medical Center, Phoenix|Ivy Brain Tumor Center|Barrow Neurological Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-500-311-70-38","December 21, 2018","July 30, 2020","December 31, 2020","February 8, 2019",,"March 10, 2020","Chandler Regional Medical Center, Chandler, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03834740"
76,"NCT01434602","Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas",,"Recruiting","No Results Available","Brain Tumor|Glioblastoma|Anaplastic Glioma","Drug: everolimus|Drug: sorafenib","Maximum tolerated dose and safety of everolimus in combination with sorafenib for patients with recurrent malignant gliomas|Median Rate of subject survival without disease progression after treatment for glioblastoma patients with no prior bevacizumab exposure|Median Rate of subject survival without disease progression after treatment for glioblastoma patients with prior bevacizumab exposure|Median Rate of subject survival without disease progression after treatment for AG patients with no prior bevacizumab exposure|Median amount of time subject survives without disease progression and the median amount of time a subject survives after therapy|Proportion of subject with tumor size reduction|Rate of patient's symptom severity and interference with function","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","118","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160011|16-C-0011","April 11, 2016","December 31, 2020","December 31, 2021","September 15, 2011",,"April 30, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01434602"
77,"NCT04181684","LITT Followed by Hypofractionated RT for Recurrent Gliomas","GCCC 19140","Recruiting","No Results Available","Glioblastoma|Brain Tumor|Glioma|Neoplasms","Device: Procedure: LITT|Radiation: Hypo-Fractionated Radiation Therapy","Adverse Events|Progression-free survival at 6 months|Median progression-free survival|Median overall survival|1-year overall survival|Overall response rate|Quality of Life before, during, and after treatment","University of Maryland, Baltimore|Keep Punching Foundation","All","22 Years and older   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00088569","January 8, 2020","February 2023","February 2023","November 29, 2019",,"January 27, 2020","University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|UCH Kaufman Cancer Center, Bel Air, Maryland, United States|Central Maryland Radiation Oncology, Columbia, Maryland, United States|Baltimore Washington Medical Center, Glen Burnie, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04181684"
78,"NCT03657576","Trial of C134 in Patients With Recurrent GBM","C134-HSV-1","Recruiting","No Results Available","Glioblastoma Multiforme of Brain|Anaplastic Astrocytoma of Brain|Gliosarcoma of Brain","Biological: C134","Measure of Treatment-Emergent Adverse Events [Safety and Tolerability]|Measure of Progression Free Survival|Measure Overall Survival|Measurement of HSV titer|Composition of the white blood cells|Measure interferon levels","University of Alabama at Birmingham|Gateway for Cancer Research|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|NIH","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-3000000571|R01CA222903","September 23, 2019","September 2022","September 2024","September 5, 2018",,"March 12, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03657576"
79,"NCT02208362","Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma",,"Recruiting","No Results Available","Malignant Glioma|Refractory Brain Neoplasm|Recurrent Brain Neoplasm|Glioblastoma","Biological: IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing Autologous T lymphocytes|Other: laboratory biomarker analysis|Other: quality-of-life assessment|Procedure: Magnetic Resonance Imaging|Procedure: Magnetic Resonance Spectroscopic Imaging|Biological: Vaccine Therapy|Other: Laboratory Biomarker Analysis|Other: Quality of Life Assessment","Incidence of grade 3 toxicity, graded using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0, the revised cytokine release syndrome grading system as well as the modified neurological grading system|Incidence of DLT, graded using NCI CTCAE version 4.0|Incidence of toxicities, graded using NCI CTCAE version 4.0 as well as the modified neurological grading system|Changes in largest length of tumor|Changes in cytokine levels|Changes in CAR T cell levels|Progression free survival|Disease response by the Response Assessment in Neuro-Oncology criteria|Overall survival (OS)|Changes in quality of life|T cell detection in tumor|IL13Ra2 antigen expression levels|Disease response from intraventricular infusion following progression after intracranial infusion (stratum 1 and 2)","City of Hope Medical Center|National Cancer Institute (NCI)|Gateway for Cancer Research|Mustang Bio, Inc.|California Institute for Regenerative Medicine (CIRM)","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","92","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13384|NCI-2014-01488|R01FD005129","May 18, 2015","May 2020","May 2020","August 5, 2014",,"April 16, 2020","City of Hope Medical Center, Duarte, California, United States",,"https://ClinicalTrials.gov/show/NCT02208362"
80,"NCT03849105","131I-IPA + XRT as Treatment for Patients With Glioblastoma Multiforme","IPAX-1","Recruiting","No Results Available","Glioblastoma Multiforme","Radiation: 4-L-[131I]iodo-phenylalanine (131I-IPA)","Safety and tolerability parameter Adverse Events|Safety parameter heart rate|Safety parameter blood pressure|Safety parameter Liver function test|Safety parameter Renal function test|Safety parameter Full Blood Count|To evaluate the maximum tolerated dose (MTD) of 131I -IPA administered concomitantly to 2nd line XRT in recurrent GBM 2|To evaluate the efficacy of a fractionated administration of 131I-IPA|Dosimetry|To explore the antineoplastic effect of 131I-IPA + XRT combination therapy|To explore the occurrence and frequency of pseudo-progression (PP) in response to 131I-IPA + XRT combination therapy|To explore the cognitive function of participants","Telix International Pty Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","131I-IPA-TLX-101-001","April 9, 2019","December 31, 2020","December 31, 2021","February 21, 2019",,"August 20, 2019","Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia|Kepler University Clinic, Linz, Austria|Medical University of Vienna, Vienna, Austria|The Netherlands Cancer Institute, Amsterdam, Netherlands|UMC Utrecht Cancer Center, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03849105"
81,"NCT01903330","ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme",,"Recruiting","No Results Available","Glioblastoma|Gliosarcoma","Drug: ERC1671|Drug: GM-CSF|Drug: Cyclophosphamide|Drug: Oral Control (Sucrose pill)|Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Drug: Bevacizumab","Safety|Efficacy|Immune Response","Daniela A. Bota|University of California, Irvine|Epitopoietic Research Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCI 13-14 ERC1671-H02|UCI 13-14|2013-9863","March 2014","March 2023","March 2023","July 19, 2013",,"November 13, 2019","University of California, Irvine, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT01903330"
82,"NCT03389230","Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma",,"Recruiting","No Results Available","Glioblastoma|HER2/Neu Positive|Malignant Glioma|Recurrent Glioma|Refractory Glioma|WHO Grade III Glioma","Biological: HER2(EQ)BBzeta/CD19t+Tcm cells|Biological: HER2(EQ)BBzeta/CD19t+Tn/mem cells|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis","Incidence of grade 3 adverse events|Dose limiting toxicities (DLT)|Incidence of adverse events|Chimeric antigen receptor (CAR) T cells detected in tumor cyst fluid, peripheral blood, and cerebrospinal fluid (CSF)|Tumor cyst fluid, peripheral blood, and cerebrospinal fluid (CSF) cytokine levels|Progression free survival|Overall Survival (OS)|Disease response|Chimeric antigen receptor (CAR) T cells detected in tumor tissue|HER2 antigen expression levels in tumor tissue","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","42","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16064|NCI-2017-01755","June 14, 2018","June 14, 2021","June 14, 2021","January 3, 2018",,"April 16, 2020","City of Hope Medical Center, Duarte, California, United States",,"https://ClinicalTrials.gov/show/NCT03389230"
83,"NCT03973918","Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG","BRAF","Recruiting","No Results Available","High Grade Glioma|BRAF V600E|BRAF V600K|Anaplastic Astrocytoma|Anaplastic Pleomorphic Xanthoastrocytoma|Gliosarcoma|Glioblastoma","Drug: Encorafenib|Drug: Binimetinib|Biological: Research Bloods|Biological: Tumor Tissue","Tumor radiographic response per RANO for 3 treatment cohorts|Progression free survival for 3 treatment cohorts|Overall Survival|Duration of response|Number of participants with adverse events as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Array BioPharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABTC 1802|UM1CA137443","July 29, 2019","July 2022","July 2023","June 4, 2019",,"March 16, 2020","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03973918"
84,"NCT02885324","Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children",,"Recruiting","No Results Available","Glioblastoma Multiforme|Anaplastic Astrocytoma|Malignant Brain Tumor|High Grade Glioma","Drug: Cabozantinib","Disease response","Indiana University","All","2 Years to 21 Years   (Child, Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IUSCC-0601","May 18, 2017","July 2021","January 2022","August 31, 2016",,"July 10, 2019","Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02885324"
